FDA — authorised 22 August 2014
- Application: NDA205551
- Marketing authorisation holder: VIIV HLTHCARE
- Local brand name: TRIUMEQ
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Triumeq in United States
FDA authorised Triumeq on 22 August 2014
Marketing authorisations
FDA — authorised 30 March 2022
- Application: NDA215413
- Marketing authorisation holder: VIIV HLTHCARE
- Status: supplemented
FDA
- Status: approved
Triumeq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Triumeq approved in United States?
Yes. FDA authorised it on 22 August 2014; FDA authorised it on 30 March 2022; FDA has authorised it.
Who is the marketing authorisation holder for Triumeq in United States?
VIIV HLTHCARE holds the US marketing authorisation.